Time to Sputum Conversion Among Patients With Drug-resistant Tuberculosis in Kenya: Retrospective Cohort Study
Abstract
The increase in cases of drug-resistant tuberculosis, particularly noted during the 1990s, represents a significant public health challenge and poses a threat to global tuberculosis control efforts. The clinical relevance of drug-resistant tuberculosis lies in the resistance to isoniazid and rifampicin, which are among the most effective anti-tuberculosis drugs currently available. On an international scale, approximately 4.1% of new tuberculosis cases and 19% of previously treated patients were reported to have multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2016. Additionally, around 8,000 cases of extensively drug-resistant tuberculosis (XDR-TB) were documented worldwide, with an estimated 6.2% of individuals with MDR-TB also having XDR-TB, according to the(World Health Organization, 2011). This study aims to examine the patterns of sputum conversion among patients diagnosed with drug-resistant tuberculosis in Kenya. Furthermore, it evaluates the existing frameworks for monitoring drug-resistant tuberculosis and identifies deficiencies in the laboratory systems used to diagnose and treat this condition.
The study objective: To assess sputum conversion in patients with drug-resistant tuberculosis and the related treatment outcomes in Kenya.
Study design and site: A retrospective cohort study design was applied to review sputum conversion time patterns for drug-resistant tuberculosis patients in Kenya.
Study population and sample: Drug-resistant patients enrolled for follow-up at Kenya's National Tuberculosis, Leprosy, and Lung Disease program...
Publisher
University of Nairobi
Rights
Attribution-NonCommercial-NoDerivs 3.0 United StatesUsage Rights
http://creativecommons.org/licenses/by-nc-nd/3.0/us/Collections
The following license files are associated with this item: